EurekaMag.com logo
+ Translate

Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration


, : Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration. American Heart Journal 112(2): 333-339

The electrophysiologic effects of a new antiarrhythmic agent, cibenzoline, were investigated in 25 patients with an average age of 62 years. The compound was administered intravenously, as a bolus given over 2 minutes, then as a slow infusion over 40 minutes. Each subject was randomly allocated to receive one of the following four doses: 1.55 mg/kg (six patients), 1.8 mg/kg (six patients), 2.2 mg/kg (six patients), or 2.6 mg/kg (seven patients). Plasma cibenzoline concentrations at these doses were 378 .+-. 80, 525 .+-. 194, 618 .+-. 72, and 731 .+-. 196 ng/ml, respectively. Administration of 1.55 mg/kg cibenzoline significantly shortened the sinus cycle (60 msec on average; p < 0.025) and increased intraatrial (+8 msec; p < 0.05) and His-Purkinje conduction times (HV interval +13 msec; p < 0.001). At 1.80 mg/kg, prolongation occurred in the HV interval (+9 msec; p < 0.02), the duration of the QRS complex (+20 msec; p > 0.05), and the QT interval (+18 msec; p < 0.025). At the higher doses these changes became more marked (maximum increase: HV = +16 msec, p < 0.001; QRS + 25msec; p < 0.001; QT + 26 msec, p < 0.05), and additional effects on atrioventricular nodal conduction time (AH interval + 17 msec; p < 0.05) and atrial (+20 msec; p < 0.05) and ventricular (+10 msec; p > 0.05) effective refractory periods were observed. Prolongation of the QRS duration was the effect that correlated best with plasma cibenzoline levels (r = 0.47; p < 0.05). These results allow an understanding of the antiarrhythmic activity of cibenzoline in humans.

Accession: 005349291

PMID: 3526853

DOI: 10.1016/0002-8703(86)90271-1

Download PDF Full Text: Electrophysiologic effects of cibenzoline in humans related to dose and plasma concentration


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Dufour A., 1985: The electrophysiological effects of intravenous cibenzoline in man with reference to dose and plasma concentration. American Heart Association Monograph: Iii-166

Boucher, M.; Dubray, C.; Kantelip, J.P.; Talmant, J.M.; Dufour, A.; Duchêne-Marullaz, P., 1989: Cardiac electrophysiological effects of cibenzoline in the conscious dog: plasma concentration-response relationships. The cardiac electrophysiological effects of cibenzoline were studied in the conscious dog. Sinus rate, corrected sinus recovery time (CSRT), and Wenckebach point (WP) were measured in six intact dogs. Atrial and ventricular rates, and atrial effec...

Mccomb J.M.; Mcgovern B.A.; Garan H.; Ruskin J.N., 1985: D sotalol electrophysiologic properties in relation to dose and to plasma concentration. American Heart Association Monograph (114): III-169

Cheymol, G.; Jaillon, P.; Lecoq, B.; Lecoq, V.; Cheymol, A.; Krumenacker, M., 1987: Cardiovascular beta-adrenergic blocking effects of bornaprolol in humans: relation to dose and plasma concentration. The cardiovascular beta-blocking effects of bornaprolol were studied in healthy male volunteers after four single oral doses. The inhibition of isoproterenol-induced tachycardia was monitored for 72 h in six subjects, and the inhibition of exercis...

Kushner, M.; Magiros, E.; Peters, R.; Carliner, N.; Plotnick, G.; Fisher, M., 1984: The electrophysiologic effects of oral cibenzoline. Five male patients with chronic stable ventricular arrhythmias underwent a placebo controlled ascending dose study with oral cibenzoline, a new type 1 antiarrhythmic drug. Ambulatory ECG (Holter) recordings and electrophysiologic studies were done...

Manz M.; Pfitzner P.; Luederitz B., 1989: Cibenzoline electrophysiologic effects in patients with supraventricular tachycardia. European Heart Journal 10(ABSTR SUPPL): 302

Gursoy S.J.A.; Steurer G.; Willems H.; Andries E.; Brugada P., 1991: Electrophysiologic effects of intravenous cibenzoline in idiopathic atrial flutter in man. European Heart Journal 12(ABSTR SUPPL): 337

Fujiki, A.; Mizumaki, K.; Tani, M.; Yoshida, S.; Sasayama, S., 1992: Electrophysiologic effects and efficacy of cibenzoline in patients with supraventricular tachycardia. Electrophysiologic effects of intravenous (i.v.) cibenzoline were evaluated in 18 patients with accessory pathways or dual atrioventricular (AV) nodal pathways (12 men and 6 women with a mean age of 44 .+-. 18 years). Twelve patients had accessory...

Atarashi, H.; Iida, K.; Kou, M.; Hirayama, Y.; Gotoh, M.; Ino, T.; Katoh, T.; Hayakawa, H., 1988: Electrophysiologic effects of intravenous cibenzoline succinate, a new class I antiarrhythmic agent. Electrophysiologic effects of cibenzoline (1.4 mg/kg/3 min), a new class I antiarrhythmic agent, were investigated in 9 patients with PSVT including WPW syndrome and 5 patients with ventricular tachycardia. Cibenzoline significantly shortened sinu...

Kuehlkamp V.; Ickrath O.; Schmid F.; Mayer F.; Haasis R.; Seipel L., 1989: Electrophysiologic effects of cibenzoline in wpw syndrome and atrioventricular nodal reentrant tachycardia. The electrophysiologic effects of the new class-1 antiarrhythmic drug cibenzoline (1.5 mg/kg within 10 min, followed by an infusion of 0.5 mg for 30 min) were investigated in six patients with atrioventricular (av) nodal reentrant tachycardia and...